Buz Investors Best Marijuana Stocks When Colorado legalized recreational marijuana on January 1, 2014, the wheels of capitalism sprang into motion. Marijuana stocks were born. Investors who feel uncomfortable with “sin stocks” such as gambling, tobacco, alcohol, and pornography ,may want to steer clear of these investments. Those who feel fine with it. however, should continue reading.
The best marijuana stocks offer investors enormous upside in a growing industry (no pun intended). They are extremely volatile in the current environment, which is an important point to remember.
Since marijuana has only been legalized at the state level, the entire industry is susceptible to a downturn. Federal law still classifies cannabis as a Schedule 1 narcotic. President Obama chose not to enforce those laws to full effect. However, the newest occupant of 1600 Pennsylvania Avenue might choose to reverse that decision. This would pose a massive risk to the industry.
The fight for marijuana legalization has been going on at a low level for years. However, it resurfaced as a national topic when Colorado held a ballot initiative during the 2014 midterm elections. To the people of that state, it was simply a vote that allowed the use of recreational marijuana; to the rest of the country, it was an experiment on the business of pot.
Here’s what happened: entrepreneurs that moved quickly collected $1.0 billion worth of sales in the year following legalization. Colorado had raised $70.0 million in taxes during that time, almost double the $42.0 million it raised from alcohol sales. (Source: “Colorado Raised More Tax Revenue From Marijuana Than From Alcohol,” Time, May 18, 2016.)
Investors looking for the top marijuana stocks of 2017 should take a closer look at Insys Therapeutics Inc (NASDAQ:INSY). This biotech company uses elements of marijuana in its medical products, which makes it an excellent hedge against policy shifts.
Its pharmaceutical version of tetrahydrocannabinol (THC) is used to treat the kind of anorexia that AIDS and cancer patients suffer from. The Food and Drug Administration (FDA) rubber stamped this drug in recent months, even while knowing that THC is the main component in marijuana. The only step left is for the drug (named “Syndros”) to be classified by the Drug Enforcement Agency (DEA).
Some readers may be surprised at our next choice: Canopy Growth Corp (TSE:CGC). Shares of CGC are highly volatile, having swung between $2.97 and $17.86. However, anyone who’s paid attention to the market over the last few months knows that Canopy Growth Corp provided investors with huge upside.
As you can tell by its name, Cara Therapeutics Inc (NASDAQ:CARA) is another medicinal play on pot stocks. This company researches, develops, and markets its own cannabis products, most of which center around pain and inflammation.
It has adapted marijuana’s key properties into medication that treats these conditions. Two of its drugs have shown considerable success in pre-clinical testing, suggesting that good things lie ahead for this stock. CARA stock has already doubled in value over the previous six months.
Click here for reuse options!